Tuberculosis treatment and management of some problems related to the medication;Abordagem terapêutica da tuberculose e resolução de alguns problemas associados à medicação

Revista Portuguesa de Pneumologia

Volumn 16, Issue 4, 2010, Pages 559-572

  Duarte, R ^a,b,c,d,j   Carvalho, A ^a,b,j   Ferreira, D ^a,j   Saleiro, S ^e,j   Lima, R ^a,j   Mota, M ^a,j   Raymundo, E ^f,j   Villar, M ^g,h,j   Correia, A ^i,j  

^a Centro Hospitalar de Vila Nova de Gaia/Espinho   (Brazil)

^b Centro Diagnóstico Pneumológico de Vila Nova de Gaia   (Brazil)

^c University of Porto   (Portugal)

^d Centro de Referência para a TBMR da Região Norte   (Brazil)

^e Hospital de Sao Joao   (Brazil)

^f Centro Diagnóstico Pneumológico de Vila Franca de Xira   (Brazil)

^g Centro Diagnóstico Pneumológico de Venda Nova   (Brazil)

^h Centro de Referência para a TBMR   (Brazil)

ⁱ Administração Regional do Norte   (Brazil)

^j Comissáde Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia ^*  (Brazil)

more..

Author keywords

Side effects; Treatment; Tuberculosis

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; HUMAN; PATIENT COMPLIANCE; TUBERCULOSIS; CLINICAL PROTOCOL; INFECTION CONTROL; INFORMATION PROCESSING; LUNG TUBERCULOSIS; REVIEW;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; DISEASE NOTIFICATION; HUMANS; MEDICATION ADHERENCE; RECORDS AS TOPIC; TUBERCULOSIS, PULMONARY;

EID: 79952110482     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0873-2159(15)30052-0     Document Type: Article

References (20)

1. DGS. Programa Nacional de Luta Contra a Tuberculose.
2. Mitchinson DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Resp Dis 1986; 133:433-430.
3. CDC - National Center for HIV/AIDS, viral hepatitis, STD and TB prevention. Core curriculum on tuberculosis, Chapter 7; 2000 Disponível em: http://www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7.html.
4. New York City Department of Health and Mental Higyene. Tuberculosis - Clinical policies and protocols. 4th Edition, 2008
5. American Thoracic Society Documents. American Thoracic Society / Centers of Disease Control and Prevention / Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
6. Chaisson RE, Clermont HC, Holt EA, Clermont HC, Holt EAM, Johnson MP, Atkinson J, Davis H, Boulos R, et al. JHU-CDS Research Team. Six -months supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-1038.
7. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899-1904.
8. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month shortcourse therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32:623-632.
9. Murray, J, Sonnenberg, P, Shearer, SC, Godfrey- Fausett, P Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733.
10. Stop TB Partnership Childhood TB Subgroup, World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children. Int J Tuberc Lung Dis 2006; 10(11):1205 1211.
11. Grupo de Trabajo de Tuberculosis de la Sociedad Española de Infectología Pediátrica (SEIP). Treatment of extrapulmonary tuberculosis and complicated forms of pulmonary tuberculosis. An Pediatr 2008; 69(3):271-278.
12. American Thoracic Society Documents. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
13. Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Curr Med Chem 2008; 15(8):809-825.
14. Bothamley G. Drug treatment for tuberculosis during pregnancy: Safety considerations. Drug Safety 24(7):553-565.
15. World Health Organization. Treatment of tuberculosis: guidelines for national programmes; 2nd edition. 1997.
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO Library Cataloguing-in-Publication Data 2006. Acessível em: http://whqlibdoc.who.int/publications/2006.
17. Zaleskis R. WHO Regional Office for Europe. Postgraduate Course ERS Copenhagen 2005. The side effects of TB therapy. Breathe 2005; 2: 69-73 Acessível em: http://www.ers-education.org/pages/default.aspx?id=610.
18. 0 19/DSCS/PNT de 17/10/2007 a 2007-10-17. Assunto: Rastreio de infecção VIH nos doentes com tuberculose. Acessível em: http://www.dgs.pt/.
19. Flores LL, Pai M, Colford JM Jr, Riley LW. In--house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta analysis and meta-regression. BMC Microbiol 2005;5:55.
20. Antunes F, Villar M, Duarte R, Brito U, Abreu A, et al. Tuberculose multirresistente. Orientações técnicas para o controlo, prevenção e vigilância em Portugal. Conclusões do seminário sobre tuberculose multiresistente. Direcção-Geral de Saúde 2008. Acessível em: http://www.dgs.pt/